Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Prognostic Value of a Composite Score Incorporating Baseline [ 18 F]FDG PET/CT and [ 68 Ga]Ga-PSMA-11 PET/CT When Screening for [ 177 Lu]Lu-PSMA Treatment Eligibility (PROFILE Study). Local targets link to admitted publications; unresolved targets remain external evidence.
10.1056/nejmoa2107322
10.1056/nejmoa2107322 · External reference
10.1016/s0140-6736(21)00237-3
10.1016/s0140-6736(21)00237-3 · External reference
10.1016/s1470-2045(23)00529-6
10.1016/s1470-2045(23)00529-6 · External reference
10.2967/jnumed.112.114116
10.2967/jnumed.112.114116 · External reference
Development of discordant hypermetabolic prostate cancer lesions in the course of [177Lu]PSMA radioligand therapy and their possible influence on patient outcome
10.3390/cancers13174270 · 2021 · External reference
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
10.1007/s00259-020-05160-8 · 2021 · External reference
10.1097/rlu.0000000000003307
10.1097/rlu.0000000000003307 · External reference
10.2967/jnumed.124.268167
10.2967/jnumed.124.268167 · External reference
Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0
10.1148/radiol.2016142043 · 2016 · External reference
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
10.1007/s00259-020-04723-z · 2020 · External reference
10.1016/s1470-2045(21)00274-6
10.1016/s1470-2045(21)00274-6 · External reference
10.2967/jnumed.118.224055
10.2967/jnumed.118.224055 · External reference
10.2967/jnumed.122.265242
10.2967/jnumed.122.265242 · External reference
10.2967/jnumed.123.267014
10.2967/jnumed.123.267014 · External reference
Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)
10.1016/j.eururo.2023.02.002 · 2023 · External reference
10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4 · External reference
Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617. A single-center prospective observational study
10.1002/pros.24518 · 2023 · External reference
Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC
10.1007/s00259-025-07198-y · 2025 · External reference
10.2967/jnumed.125.270804
10.2967/jnumed.125.270804 · External reference
Metabolic crosstalk in the metastatic prostate cancer–bone microenvironment: mechanism, detection and therapeutic strategies
10.1016/j.ejphar.2026.178611 · 2026 · External reference
Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker
10.3389/fmed.2023.1339160 · 2023 · External reference
Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT
10.1038/s41598-024-61961-z · 2024 · External reference
10.1148/radiol.233460
10.1148/radiol.233460 · External reference
Multicentre quantitative 68Ga PET/CT performance harmonisation
10.1186/s40658-019-0253-z · 2019 · External reference
10.2967/jnumed.117.202861
10.2967/jnumed.117.202861 · External reference
Underestimation of 68Ga PET/CT SUV caused by activity overestimation using default calibrator settings
10.1016/j.ejmp.2019.03.006 · 2019 · External reference
10.1038/s41585-024-00900-z
10.1038/s41585-024-00900-z · External reference
10.2967/jnmt.125.271978
10.2967/jnmt.125.271978 · External reference
Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial
10.1016/j.eclinm.2024.102862 · 2024 · External reference
10.1007/s00259-021-05525-7
10.1007/s00259-021-05525-7 · External reference
Prognostic value of baseline alkaline phosphatase of 177Lu‐PSMA radioligand therapy in metastatic castration‐resistant prostate cancer: a systematic review and meta‐analysis
10.1371/journal.pone.0307826 · 2024 · External reference
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up
10.1007/s00259-022-05853-2 · 2022 · External reference
10.2967/jnumed.125.271825
10.2967/jnumed.125.271825 · External reference
10.1007/s00259-017-3740-2
10.1007/s00259-017-3740-2 · External reference
